Overview

LANN-study: Lantus, Amaryl, Novorapid, Novomix Study

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Many diabetics gain weight while on insulin therapy. In this study, we evaluate the efficacy of the combination of glimepiride and short-acting insulin on weight control and glucose control. In this study, 150 diabetics whose diabetic control is inadequate while on maximal oral treatment will be randomized to either the new combination treatment or twice daily injections with a mixture of short- and longacting insulin or once-daily injection with a basal insulin analog. The study will compare glucose control and weight gain during a year after randomisation between the three treatments.
Phase:
Phase 3
Details
Lead Sponsor:
Rijnstate Hospital
Treatments:
Glimepiride
Insulin Aspart
Insulin aspart, insulin aspart protamine drug combination 30:70
Insulin Glargine